On the other hand, tumor cells express suppressive molecules (such as indoleamine 2,3-dioxygenase (IDO), adenosine, and CCL2) to inhibit T-cell activity and recruit Tregs to tumor sites, impairing immunotherapy efficacy [21–23]. The gene discussed is IDO1; the disease is neoplasm.